Evolving Oncologic Development In The Decade Ahead

Successive revolutions of prevention strategies and precision medicine in the past two decades have contributed to lowering the mortality rate for the ten most prevalent cancers by more than 10% across most of Europe, Asia, and North America1. In the coming years, emergent therapeutic strategies, including immuno-oncologics and liquid biopsy-based companion diagnostics, may yield some of the most transformative clinical benefits to date.

Yet, oncology pipelines remain rife with challenges, such as suppressing the escalating timelines and costs of clinical development, demonstrating cost-effectiveness, and tuning enrolment to overcome the twin obstacles of difficult-to-access patient populations and heterogeneous patient responses.

To explore how development strategies can continue to evolve, we asked Dr. Ira Spector, EVP, Analytics and Consulting, and Dr. Cyril Clarke, VP Translational Medicine for their insights into transforming the productivity of oncology pipelines.